Core Viewpoint - The news highlights the performance and business operations of Haiprime, a leading multinational pharmaceutical company in China, focusing on its revenue structure, market position, and recent financial results. Company Overview - Haiprime was established in 1998 and is headquartered in Shenzhen, China, with a dual financing platform (A+H shares) [2] - The company specializes in the heparin industry chain, biopharmaceutical CDMO services, and the investment, development, and commercialization of innovative drugs [2][7] - As of September 30, 2025, Haiprime reported a revenue of 4.194 billion yuan, a year-on-year increase of 3.09%, while the net profit attributable to shareholders decreased by 29.04% to 554 million yuan [7] Revenue Composition - The revenue composition of Haiprime is as follows: 63.06% from formulations, 18.59% from CDMO services, 16.05% from heparin sodium and low molecular weight heparin raw materials, and 2.30% from other sources [7] Market Performance - On November 7, Haiprime's stock rose by 0.91%, with a trading volume of 41.4586 million yuan and a turnover rate of 0.27%, bringing the total market capitalization to 17.989 billion yuan [1] - The company benefits from a high overseas revenue ratio of 93.04%, which is positively impacted by the depreciation of the Chinese yuan [3] Shareholder Information - As of September 30, 2025, Haiprime had 27,000 shareholders, an increase of 2.60% from the previous period [7] - The top ten circulating shareholders include Hong Kong Central Clearing Limited, which holds 12.0093 million shares, an increase of 691,700 shares from the previous period [9] Dividend Distribution - Since its A-share listing, Haiprime has distributed a total of 4.21 billion yuan in dividends, with 514 million yuan distributed over the past three years [8]

Core Viewpoint - Haiprime, a leading multinational pharmaceutical company, is benefiting from the depreciation of the RMB and has a strong focus on the heparin industry chain, biopharmaceutical CDMO, and innovative drug development [2][3]. Company Overview - Haiprime was established in 1998 in Shenzhen and has both A and H share financing platforms. The company aims to provide high-quality, safe, and effective drugs and services to global patients [2]. - The main business segments of Haiprime include heparin raw materials, downstream low molecular weight heparin products, and biopharmaceutical CDMO services [7]. Financial Performance - For the first half of 2025, Haiprime reported a revenue of 2.817 billion yuan, a year-on-year decrease of 0.71%, and a net profit attributable to shareholders of 422 million yuan, down 36.44% year-on-year [7]. - As of June 30, 2025, overseas revenue accounted for 93.04% of total revenue, benefiting from the depreciation of the RMB [3]. Shareholder Information - As of June 30, 2025, Haiprime had 26,300 shareholders, a decrease of 7.29% from the previous period. The average circulating shares per person remained at 0 [7]. - The company has distributed a total of 4.21 billion yuan in dividends since its A-share listing, with 514 million yuan distributed over the past three years [8]. Market Activity - On October 29, Haiprime's stock price increased by 0.75%, with a trading volume of 41.3352 million yuan and a turnover rate of 0.28%, bringing the total market capitalization to 17.637 billion yuan [1].

Core Viewpoint - Haiprime is a leading multinational pharmaceutical company with a focus on heparin, biopharmaceutical CDMO, and innovative drug development, benefiting from the depreciation of the RMB and a strong overseas revenue stream [2][3]. Company Overview - Established in 1998 in Shenzhen, Haiprime operates with A+H dual financing platforms and aims to provide high-quality, safe, and effective drugs and services globally [2]. - The main business segments include heparin industry chain, biopharmaceutical CDMO, and innovative drug investment, development, and commercialization [2][7]. - As of June 30, 2025, Haiprime reported a revenue of 2.817 billion yuan, a year-on-year decrease of 0.71%, and a net profit of 422 million yuan, down 36.44% year-on-year [7]. Financial Performance - The company’s overseas revenue accounted for 93.04% of total revenue, benefiting from the depreciation of the RMB [3]. - The revenue composition includes 63.06% from formulations, 18.59% from CDMO, 16.05% from heparin sodium and low molecular weight heparin raw materials, and 2.30% from other sources [7]. - Cumulative cash dividends since the A-share listing amount to 4.21 billion yuan, with 514 million yuan distributed over the past three years [8]. Market Activity - On October 27, Haiprime's stock rose by 0.84%, with a trading volume of 46.599 million yuan and a market capitalization of 17.622 billion yuan [1]. - The stock has seen a net inflow of 2.6047 million yuan from major investors today, indicating a slight increase in interest [4]. Technical Analysis - The average trading cost of the stock is 11.56 yuan, with the current price fluctuating between resistance at 12.80 yuan and support at 11.53 yuan, suggesting potential for range trading [6].

Core Viewpoint - The company Haiprui is a leading multinational pharmaceutical enterprise with a focus on the heparin industry chain, biopharmaceutical CDMO, and innovative drug development, benefiting from the depreciation of the RMB and a strong overseas revenue base [2][3]. Company Overview - Haiprui was established in 1998 in Shenzhen and has both A and H share financing platforms. Its main business includes the heparin industry chain, biopharmaceutical CDMO, and innovative drug investment, development, and commercialization [2]. - The company’s revenue composition includes 63.06% from formulations, 18.59% from CDMO, 16.05% from heparin sodium and low molecular weight heparin raw materials, and 2.30% from other sources [7]. Financial Performance - For the first half of 2025, Haiprui reported a revenue of 2.817 billion yuan, a year-on-year decrease of 0.71%, and a net profit attributable to shareholders of 422 million yuan, down 36.44% year-on-year [7]. - As of June 30, 2025, the company had a total market capitalization of 17.564 billion yuan [1]. Market Position - The company has a significant overseas revenue share of 93.04%, which is positively impacted by the depreciation of the RMB [3]. - The stock has shown a recent trading volume of 46.8377 million yuan with a turnover rate of 0.31% [1]. Shareholder Information - As of June 30, 2025, Haiprui had 26,300 shareholders, a decrease of 7.29% from the previous period [7]. - The top ten circulating shareholders include Hong Kong Central Clearing Limited, which increased its holdings by 6.3765 million shares [9]. Dividend History - Since its A-share listing, Haiprui has distributed a total of 4.21 billion yuan in dividends, with 514 million yuan distributed over the past three years [8].

Core Viewpoint - The market showed mixed performance with the Shanghai Composite Index slightly declining while the North Exchange 50 Index gained strength, indicating a potential recovery in investor sentiment and market dynamics [1] Market Performance - The Shanghai Composite Index closed down 0.07% at 3913.76 points, the Shenzhen Component Index fell 0.62% to 12996.61 points, and the ChiNext Index decreased by 0.79% to 3059.32 points [1] - The North Exchange 50 Index increased by 0.87%, with a total trading volume across the Shanghai, Shenzhen, and North exchanges reaching 16,905 billion [1] Sector Analysis - Sectors such as coal, non-ferrous metals, brokerage, and semiconductors experienced declines, while oil and real estate sectors showed strong gains [1] - Banking, pharmaceuticals, and retail sectors also saw upward movement, with emerging concepts like lab-grown meat, marine economy, and biovaccines becoming active [1] Investment Strategy - According to China Merchants Securities, there is still an inflow of incremental capital into the market, with strong investor willingness to accumulate positions at lower levels, suggesting a potential market rebound [1] - Short-term focus should be on previously popular sectors such as domestic computing power, semiconductor autonomy, controllable nuclear fusion, military industry, and commercial aerospace, while long-term strategies should consider the potential economic resonance between China and the U.S. in 2026 and the trend of PPI recovery, emphasizing low-position cyclical sectors [1]

Core Viewpoint - The market is experiencing a downward trend with the Shanghai Composite Index falling by 0.44% and various sectors such as coal and non-ferrous metals declining, while the artificial meat concept remains active [1] Market Performance - As of the midday close, the Shanghai Composite Index is at 3899.05 points, down 0.44%, the Shenzhen Component is down 0.81%, and the ChiNext Index is down 0.89%. In contrast, the North China 50 Index has risen by 1.19% [1] - The total trading volume across the Shanghai, Shenzhen, and North exchanges reached 1.1142 trillion yuan [1] Sector Analysis - Sectors such as coal, non-ferrous metals, semiconductors, and brokerage firms are experiencing declines, while engineering machinery, real estate, oil, and pharmaceuticals are seeing gains. The artificial meat, industrial mother machines, and biological vaccine concepts are particularly active [1] Economic Outlook - Dongguan Securities indicates that the index has reached a high point, leading to increased capital divergence and potential short-term fluctuations due to profit-taking. However, as tariff disturbances are gradually resolved, the economy is expected to continue recovering in the fourth quarter supported by policy measures [1] - The expectation of interest rate cuts by the Federal Reserve may attract foreign capital inflows, while the decline in domestic risk-free interest rates enhances the investment value of A-shares, potentially driving more domestic capital into the stock market [1] Investment Strategy - The market may face short-term fluctuations, but the medium-term upward trend is expected to continue. It is advised to maintain flexible positions, avoid blind chasing of highs, and actively adjust holdings based on economic conditions and valuation [1]

来源：新浪证券-红岸工作室 10月21日，海普瑞涨2.14%，成交额3977.35万元，换手率0.27%，总市值175.20亿元。 异动分析 创新药+生物疫苗+CRO概念+人民币贬值受益 1、2024年年报，海普瑞于 1998 年成立于深圳，是拥有 A+H 双融资平台的领先跨国制药企业，主要业 务覆盖肝素产业链、生物大分子 CDMO 和创新药物的投资、开发及商业化，致力于为全球患者带去高 质量的安全有效药物和服务，护佑健康。 2、赛湾生物具备向客户提供mRNA疫苗开发及生产CDMO服务的能力。赛湾生物凭借优秀的工艺开 发、准时交付以及成功的运营能力，继续推进mRNA疫苗供应链的工作，支持全球多个已商业化的 mRNA疫苗的生产。 3、深圳市海普瑞药业集团股份有限公司的主营业务是肝素产业链，生物大分子CDMO和创新药物的投 资，开发及商业化。 4、根据2024年年报，公司海外营收占比为93.04%，受益于人民币贬值。 (免责声明：分析内容来源于互联网，不构成投资建议，请投资者根据不同行情独立判断) 资金分析 今日主力净流入348.42万，占比0.09%，行业排名40/158，该股当前无连续增减仓现象，主力趋势不明 ...

Core Viewpoint - Haiprime is a leading multinational pharmaceutical company with a focus on heparin, biopharmaceutical CDMO, and innovative drug development, benefiting from the depreciation of the RMB and a strong overseas revenue stream [2][3]. Company Overview - Established in 1998 in Shenzhen, Haiprime operates with both A and H share financing platforms, primarily engaged in the heparin industry chain, biopharmaceutical CDMO, and innovative drug investment, development, and commercialization [2]. - The company's main business revenue composition includes: 63.06% from formulations, 18.59% from CDMO, 16.05% from heparin sodium and low molecular weight heparin raw materials, and 2.30% from other sources [7]. Financial Performance - For the first half of 2025, Haiprime reported a revenue of 2.817 billion yuan, a year-on-year decrease of 0.71%, and a net profit attributable to shareholders of 422 million yuan, down 36.44% year-on-year [7]. - As of June 30, 2025, the company had a total market capitalization of 17.153 billion yuan, with a trading volume of 35.1323 million yuan on October 20, 2023 [1][7]. Market Position - Haiprime's overseas revenue accounted for 93.04% of its total revenue, benefiting from the depreciation of the RMB [3]. - The company is positioned within the pharmaceutical and biotechnology sector, specifically in chemical pharmaceuticals and chemical preparations [7]. Shareholder Information - As of June 30, 2025, Haiprime had 26,300 shareholders, a decrease of 7.29% from the previous period, with an average of 0 shares per shareholder [7]. - The top ten circulating shareholders include Hong Kong Central Clearing Limited, which increased its holdings by 6.3765 million shares to 11.3176 million shares [9]. Dividend Distribution - Since its A-share listing, Haiprime has distributed a total of 4.21 billion yuan in dividends, with 514 million yuan distributed over the past three years [8].

Core Viewpoint - The company, Haiprui, is a leading multinational pharmaceutical enterprise with a focus on the heparin industry chain, biopharmaceutical CDMO, and innovative drug development, benefiting from the depreciation of the RMB and a significant overseas revenue share [2][3]. Company Overview - Haiprui was established in 1998 in Shenzhen and has both A and H share financing platforms [2]. - The main business segments include heparin raw materials, low molecular weight heparin products, and biopharmaceutical CDMO services [7]. - As of June 30, 2025, the company reported a revenue of 2.817 billion yuan, a year-on-year decrease of 0.71%, and a net profit of 422 million yuan, down 36.44% year-on-year [7]. Financial Performance - The overseas revenue accounted for 93.04% of total revenue, benefiting from the depreciation of the RMB [3]. - The company has distributed a total of 4.21 billion yuan in dividends since its A-share listing, with 514 million yuan distributed in the last three years [8]. Market Activity - On October 16, Haiprui's stock price decreased by 0.17%, with a trading volume of 45.1938 million yuan and a turnover rate of 0.31%, resulting in a total market capitalization of 17.299 billion yuan [1]. - The stock's average trading cost is 11.57 yuan, with current price fluctuations between resistance at 12.33 yuan and support at 11.16 yuan [6]. Shareholder Information - As of June 30, 2025, the number of shareholders decreased by 7.29% to 26,300, with no circulating shares per person [7]. - The eighth largest shareholder is Hong Kong Central Clearing Limited, holding 11.3176 million shares, an increase of 6.3765 million shares from the previous period [9].

Core Viewpoint - The company, Haiprui, is a leading multinational pharmaceutical enterprise with a focus on the heparin industry chain, biopharmaceutical CDMO, and innovative drug development, benefiting from the depreciation of the RMB and a significant overseas revenue share [2][3]. Company Overview - Haiprui was established in 1998 in Shenzhen and has both A and H share financing platforms [2]. - The main business segments include heparin raw materials, downstream low molecular weight heparin products, and CDMO services for biopharmaceuticals [7]. - As of June 30, 2025, Haiprui reported a revenue of 2.817 billion yuan, a year-on-year decrease of 0.71%, and a net profit of 422 million yuan, down 36.44% year-on-year [7]. Financial Performance - The company’s overseas revenue accounted for 93.04% of total revenue, benefiting from the depreciation of the RMB [3]. - The average trading cost of the stock is 11.57 yuan, with the current stock price fluctuating between resistance at 12.33 yuan and support at 11.16 yuan [6]. Shareholder Information - As of June 30, 2025, the number of shareholders decreased by 7.29% to 26,300 [7]. - The company has distributed a total of 4.21 billion yuan in dividends since its A-share listing, with 514 million yuan distributed over the past three years [8]. Market Activity - On October 14, Haiprui's stock fell by 1.53%, with a trading volume of 59.5826 million yuan and a turnover rate of 0.41%, resulting in a total market capitalization of 16.962 billion yuan [1].